Resources Repository
-
DataPublication 2019Global Multidimensional Poverty Index 2019: Illuminating Inequalities
This data publication developed by the United Nations Development Programme (UNDP) and the Oxford Poverty …
This data publication developed by the United Nations Development Programme (UNDP) and the Oxford Poverty and Human Development Initiative (OPHI) offers data for 101 countries and 5.7 billion people, comparing acute multidimensional poverty at regional, national, and subnational levels using the global Multidimensional Poverty Index (MPI). The global MPI, developed by the OPHI in 2010, is one tool to comprehensively measure progress towards Sustainable Development Goal (SDG) 1, which aims to end poverty in all…
Health Outcomes | Global | Social Determinants | Health Systems | Climate/Environment | Economics/Finance | Education/Labor -
ArticlePublication 2019Systematic Review of Economic Evaluations of Vaccination Strategies Against Tuberculosis
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited …
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis, but its effectiveness is limited and varies by age, so a valid cost-effectiveness study is needed to assist decision-makers in the implementation of cost-effective strategies for BCG vaccination. Using the Quality of Health Economic Studies (QHES) instrument, the authors assessed the quality of published studies involving economic evaluations of BCG vaccination strategies in a variety of regions, target populations, and vaccine types. Most of the…
Evidence Synthesis | Global | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2018Comparing Cost-per-QALYs Gained to Cost-per-DALYs Averted
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, …
The authors examined 6,438 cost-per-QALY and 543 cost-per-DALY studies published through 2016 using two databases, the Tufts Medical Center CEA Registry (cost-per-QALY gained studies), and the Global Cost-Effectiveness Analysis (GHCEA) Registry (cost-per-DALY averted studies). Study characteristics that were analyzed included intervention type, sponsor, country, primary disease, and number of CEAs versus disease burden estimates for major conditions. The authors report that cost-per-QALY studies were most often about pharmaceuticals or interventions in high-income countries while cost-per-DALY…
Evidence Synthesis | Global | Policy/Regulation | Cost-Effectiveness Analysis | Health/Medicine -
Resource PackPublication, Teaching Resource 2018Resource Pack: Economic Evaluation Guidelines
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure …
This resource pack includes guidelines for health economic evaluation - methods designed to identify, measure and value the incremental resources used, relative to benefits gained, of alternative interventions or policies - with the goal of improving resource allocation decisions by addressing efficiency in healthcare. The selected examples focus predominantly on the conduct of cost-effectiveness analysis. Over the past three decades, cost-effectiveness analysis has gained increasing attention from decision makers in both resource-rich and resource-poor countries.…
Priority Setting/Ethics | Global | Policy/Regulation | Preferences/Values | Costing Methods | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health Systems | Climate/Environment | Economics/Finance | Government/Law | Health/Medicine | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
Lesson/ModuleVideo, Teaching Resource 2018How Can Cost Effectiveness Analysis be Made More Relevant to U.S. Health Care?
This video is intended to provide an overview of how cost-effectiveness analysis is used to …
This video is intended to provide an overview of how cost-effectiveness analysis is used to guide health policy decisions in other countries and identify barriers to using these findings in the U.S., along with tips on how to increase the chances that these findings will be implemented. This video is part of the Conducting Cost-Effectiveness Analysis with VA Data (HCEA) free course offered by the U.S. Department of Veterans Affairs Health Services Research and Development…
Priority Setting/Ethics | Global | Policy/Regulation | Cost-Effectiveness Analysis | Health/Medicine | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
GuidelinesPublication 2018Latent TB Infection: Updated & Consolidated Guidelines for Programmatic Management
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation …
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB. Up to one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and on average, 5–10% of those who are infected will develop active TB disease over their lifetime. The management of LTBI involves a comprehensive package of interventions: identifying and testing those individuals…
Evidence Synthesis | Global | Infectious Diseases | Health/Medicine -
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Cervical Cancer Models
This resource pack, curated by the Center for Health Decision Science, is a collection of …
This resource pack, curated by the Center for Health Decision Science, is a collection of models of HPV-related cervical cancer, differing in design, structure and features based on analytic objectives. In many ways, HPV and its related diseases represent a prototypical public health problem given the communicable and non-communicable nature of disease, opportunities for intervention along the entire disease spectrum (e.g., primary and secondary prevention, diagnosis, treatment), the varied ages at which interventions are targeted…
Calibration/Validation | Global | Infectious Diseases | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Clinical Care | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology -
ArticlePublication 2017Costing of National STI Program Implementation, 2016-2021
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) …
In 2016 the World Health Assembly adopted the Global Strategy on Sexually Transmitted Infections (STI) 2016–2021 aiming to reduce curable STIs by 90% by 2030. This analysis costed scaling-up priority interventions to achieve coverage targets. Strategy-targeted declines in Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum and Trichomonas vaginalis were applied to WHO-estimated regional burdens at 2012 levels. Case management was costed for the curable STIs, symptomatic Herpes Simplex Virus 2 (HSV-2), and non-STI vaginal syndromes, with incrementally expanding diagnoses. Service…
Evidence Synthesis | Global | Infectious Diseases | Costing Methods | Clinical Care | Economics/Finance | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Global | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | North America